Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry.

Autor: Ki YJ; Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of Korea., Park KW; Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of Korea., Kang J; Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of Korea., Kim CH; Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of Korea., Han JK; Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of Korea., Yang HM; Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of Korea., Kang HJ; Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of Korea., Koo BK; Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of Korea., Kim HS; Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of Korea.
Jazyk: angličtina
Zdroj: Journal of interventional cardiology [J Interv Cardiol] 2020 Feb 26; Vol. 2020, pp. 3872704. Date of Electronic Publication: 2020 Feb 26 (Print Publication: 2020).
DOI: 10.1155/2020/3872704
Abstrakt: Objective: In this study, we sought to compare the efficacy and safety of the Xience Prime/Xience V/Promus EES and Biomatrix/Biomatrix Flex/Nobori BES with resolute integrity/resolute ZES using the grand drug-eluting stent (Grand-DES) registry.
Background: Currently, new-generation drug-eluting stents (DESs) are used as the standard of care in patients undergoing percutaneous coronary intervention. No study has simultaneously compared everolimus-eluting stent (EES), biolimus-eluting stent (BES), and zotarolimus-eluting stent (ZES).
Methods: Stent-related composite outcomes (target lesion failure) and patient-related composite outcomes were compared in crude and propensity score-matched analysis.
Results: Of the 17,286 patients in the Grand-DES group, 5,137, 2,970, and 4,990 patients in the EES, BES, and ZES groups completed a three-year follow-up. In the propensity score-matched cohort, the stent-related outcome (EES vs. BES vs. ZES; 5.9% vs. 6.7% vs. 7.1%, P = 0.226) and patient-related outcomes (12.7% vs. 13.5% vs. 14.3%, P = 0.226) and patient-related outcomes (12.7% vs. 13.5% vs. 14.3%, P = 0.226) and patient-related outcomes (12.7% vs. 13.5% vs. 14.3%, P = 0.226) and patient-related outcomes (12.7% vs. 13.5% vs. 14.3%.
Conclusions: In this robust real-world registry with unrestricted use of EES, BES, and ZES, the three stent groups showed comparable safety and efficacy at the 3-year follow-up.
Competing Interests: There are no conflicts of interest.
(Copyright © 2020 You-Jeong Ki et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje